去年，阿尔尼拉姆制药公司表现最佳的业务板块AMVUTTRA实现营收2.31B美元。United States的营收贡献最高，去年达到2.07B美元。最近一个季度，截至2026-06-30，阿尔尼拉姆制药公司表现最佳的业务板块AMVUTTRA实现营收1.01B美元。United States的营收贡献最高，达到895.49M美元。

业务

营业收入

占比

年报

年报

单季报

AMVUTTRA

Roche

GIVLAARI

Other

OXLUMO

ONPATTRO

Regeneron Pharmaceuticals

Novartis AG

Vir Biotechnology

FY2025

FY2024

FY2023

FY2022

FY2021

AMVUTTRA

2.31B(62.30%)

970.45M(43.16%)

557.84M(30.51%)

93.80M(9.04%)

--(--)

Roche

394.88M(10.63%)

119.49M(5.31%)

--(--)

GIVLAARI

308.49M(8.31%)

255.87M(11.38%)

219.25M(11.99%)

173.14M(16.69%)

127.81M(15.14%)

Other

218.55M(5.88%)

99.97M(4.45%)

399.62M(21.86%)

10.33M(1.00%)

2.91M(0.34%)

OXLUMO

191.44M(5.15%)

167.05M(7.43%)

109.84M(6.01%)

69.78M(6.73%)

59.59M(7.06%)

ONPATTRO

172.79M(4.65%)

252.86M(11.25%)

354.55M(19.39%)

557.61M(53.75%)

474.74M(56.23%)

Regeneron Pharmaceuticals

113.96M(3.07%)

302.80M(13.47%)

100.47M(5.50%)

87.84M(8.47%)

113.23M(13.41%)

Novartis AG

--(--)

79.76M(3.55%)

86.73M(4.74%)

43.16M(4.16%)

49.12M(5.82%)

Vir Biotechnology

--(--)

1.75M(0.17%)

16.90M(2.00%)

地区

营业收入

占比

年报

年报

单季报

United States

Europe

Net revenues from collaborations

Rest of World

Royalty revenue

Rest of World

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

United States

2.07B(55.67%)

933.54M(41.52%)

689.02M(37.69%)

615.72M(59.35%)

506.98M(60.05%)

325.70M(66.09%)

Europe

651.09M(17.53%)

516.30M(22.96%)

399.34M(21.84%)

314.86M(30.35%)

260.28M(30.83%)

120.09M(24.37%)

Net revenues from collaborations

553.37M(14.90%)

510.22M(22.69%)

546.18M(29.87%)

--(--)

Rest of World

267.93M(7.21%)

--(--)

Royalty revenue

174.02M(4.69%)

91.79M(4.08%)

40.63M(2.22%)

--(--)

Rest of World

--(--)

196.39M(8.74%)

153.12M(8.37%)

106.84M(10.30%)

77.03M(9.12%)

47.06M(9.55%)